Clinical Trials

Carcinoma, Squamous Cell

NCT04858269 2026-03-24

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Phase 2 Recruiting

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05027633 2026-03-20

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

Phase 2 Recruiting

35 enrolled

Carcinoma, Squamous Cell

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

7 enrolled 11 charts

Carcinoma, Squamous Cell

NCT06041802 2026-02-17

MK-3475A-E39

19 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04808999 2025-05-29

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

30 enrolled 10 charts

Carcinoma, Squamous Cell

NCT02289209 2025-03-06

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

48 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04357873 2025-02-19

PEVOsq

GastrointestinalGenitourinaryGynecologicHead & Neck

112 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT03284424 2024-08-23

MK-3475-629

159 enrolled 16 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02777385 2024-08-01

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

80 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

5 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT02883556 2021-01-13

CARSKIN

57 enrolled